An anti-aging compound of nicotinamide ergothioneine and its preparation method and application

Abstract

The application discloses an anti-aging ergothioneine and nicotinamide compound preparation and a preparation method and application thereof, and belongs to the technical field of cosmetic health products. The compound preparation takes pyrroloquinoline quinone, ergothioneine and nicotinamide as the core, and is matched with betaine, trehalose, quercetin phospholipid complex, alpha-lipoic acid and N-acetyl cysteine in specific proportions. The anti-aging ergothioneine and nicotinamide compound preparation and the preparation method and application thereof are adopted, the components such as PQQ, ergothioneine, nicotinamide and quercetin phospholipid complex are synergistically used, and the synchronous activation of mitochondrial regeneration, energy metabolism, free radical targeted removal and mitochondrial mass control is realized for the first time. The compound preparation can be prepared into cosmetics for external use on the skin, and the effects of antioxidation and skin barrier repair can be achieved.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, and in particular to an anti-aging ergothioneine-nicotinamide compound preparation, its preparation method, and its application. Background Technology

[0002] Aging is a complex biological process in which the functions of cells, tissues, and organs gradually decline over time. Its core mechanisms involve mitochondrial dysfunction, accumulation of oxidative stress, and NAD+. + Multiple factors contribute to skin aging, including decreased levels of collagen and weakened cell repair capabilities. As the largest organ in the human body, the skin's aging is particularly evident. Excessive accumulation of free radicals leads to collagen loss and elastin fiber breakage, resulting in problems such as dullness, fine lines, and impaired barrier function.

[0003] Most commercially available anti-aging products currently use a single active ingredient, such as PQQ, niacinamide, or ergothioneine alone. These products target only a single point of action and cannot cover the multiple pathways of aging. PQQ can promote mitochondrial regeneration, and niacinamide acts as an NAD+ receptor agonist. + The precursor can enhance cellular energy metabolism, while ergothioneine is a highly effective free radical scavenger. However, when used alone, it cannot form a systemic anti-aging effect and has limited effects on improving dull skin, fine lines, and fatigue.

[0004] Some products attempt to simply combine multiple active ingredients, but face significant technical hurdles. Ergot thiourea is easily degraded by light and oxygen during processing and storage, resulting in poor compatibility and insufficient actual effective dose, making it difficult to exert a sustained effect of scavenging free radicals in the skin and body. Quercetin and other ingredients can activate mitochondrial quality control pathways and inhibit NAD+. + The consumed active ingredients, due to their low transdermal absorption rate, are difficult to fully exert their regulatory advantages on skin cell energy metabolism in practical applications.

[0005] Therefore, there is an urgent need to develop an anti-aging composition that has multi-target synergy, stable components, high bioavailability, and can effectively scavenge free radicals and repair the skin barrier for a long time. Summary of the Invention

[0006] The purpose of this invention is to provide an anti-aging ergothioneine-nicotinamide compound preparation, its preparation method, and its application, in order to solve the above-mentioned problems.

[0007] This invention provides an anti-aging ergothioneine-nicotinamide compound preparation, which comprises, based on 100 parts by weight of pyrroloquinoline quinone (PQQ), ergothioneine, and nicotinamide: Pyrroloquinoline quinone (PQQ) 30-36 parts by weight; Ergothioneine 28–34 parts by weight; 32-38 parts by weight of nicotinamide; It also contains: 3 to 15 parts by weight of betaine; Trehalose 5-25 parts by weight; 10-40 parts by weight of quercetin phospholipid complex, wherein the quercetin phospholipid complex is pre-combined from quercetin and phospholipids in a mass ratio of 1:1 to 1:3; 5-20 parts by weight of α-lipoic acid; 10-30 parts by weight of N-acetylcysteine.

[0008] Preferably, pyrroloquinoline quinone is selected from at least one of pyrroloquinoline quinone disodium salt, pyrroloquinoline quinone free acid or its derivatives; ergothione is L-ergothione; and α-lipoic acid is R-α-lipoic acid.

[0009] Preferably, the compound preparation further comprises one or more of the following: 5-50 parts by weight of urolithin A, 1-10 parts by weight of spermidine, 10-50 parts by weight of coenzyme Q10, and 50-200 parts by weight of hydrolyzed collagen peptides; during preparation, one or more of urolithin A, spermidine, coenzyme, and hydrolyzed collagen peptides are added in step (c), and the premix A, the ergothioneine-trehalose glassy microparticles, the quercetin phospholipid complex, α-lipoic acid and N-acetylcysteine, and one or more of urolithin A, spermidine, coenzyme, and hydrolyzed collagen peptides are subjected to gradient homogenization.

[0010] Preferably, pharmaceutically acceptable excipients include at least one of fillers, binders, disintegrants, lubricants, sweeteners, flavorings, and gliding agents.

[0011] A method for preparing the anti-aging ergothioneine-nicotinamide compound as described above is provided, comprising the following steps: (a) Pyrroloquinoline quinone, nicotinamide and betaine were ground and mixed under nitrogen protection and at a low temperature of -50℃ to -80℃ to obtain premix A; (b) Ergothioneine and trehalose were dissolved in deionized water at a mass ratio of 1:2 to 1:5 and then spray-dried to produce ergothioneine-trehalose glassy microparticles. (c) The premix A, the ergothioneine-trehalose glassy microparticles, the quercetin phospholipid complex, α-lipoic acid and N-acetylcysteine ​​are subjected to gradient homogenization, starting at a speed of 1000-2000 rpm and gradually increasing to 5000-8000 rpm to obtain an active mixture. (d) The active mixture is mixed with pharmaceutically acceptable excipients and shaped into a selected dosage form to obtain the anti-aging composition.

[0012] Preferably, the temperature of the low-temperature grinding in step (a) is -60℃ to -70℃, and the nitrogen purity is above 99.9%.

[0013] Preferably, the gradient homogenization in step (c) adopts the following procedure: mix at 1000-1500 rpm for 1-3 minutes, then increase the speed by 500-1000 rpm each time, mix for 1-2 minutes after each increase, until 5000-8000 rpm is reached and continue mixing for 3-5 minutes.

[0014] Preferably, before step (d), the active mixture is treated with liposome encapsulation technology: the active mixture is dissolved in an organic solvent with phospholipids and cholesterol at a mass ratio of (3-6):1, and a lipid film is formed by vacuum evaporation. The lipid suspension is obtained by adding buffer solution for hydration, and then freeze-drying or spray-drying to make solid liposome powder, which is then mixed with excipients to form a solid liposome powder.

[0015] This invention provides an application of the anti-aging ergothioneine-nicotinamide compound as described above, for the preparation of a topical skin formulation, which is a cosmetic with antioxidant and skin barrier repair functions.

[0016] Therefore, the present invention, employing the above-mentioned anti-aging ergothioneine-nicotinamide compound preparation, its preparation method, and its application, has the following beneficial effects: (1) The compound formulation, with PQQ, ergothioneine, and nicotinamide as its core components, supplemented by quercetin phospholipid complex, α-lipoic acid, and N-acetylcysteine, achieves for the first time the synergistic activation of mitochondrial regeneration, energy metabolism, free radical targeted scavenging, and mitochondrial quality control. Among them, the bioavailability of quercetin is significantly improved after being compounded with phospholipids, and it can inhibit CD38 enzyme activity and reduce NAD. + Consumption, and bidirectional metabolic regulation with nicotinamide, breaks through the limitations of single-component effects.

[0017] (2) By using the intermolecular hydrogen bond between betaine and ergothioneine, combined with the glassy embedding matrix formed by spray drying of trehalose, a dual protection system of hydrogen bond and glassy state is constructed, which effectively solves the problem of easy degradation of ergothioneine in compound preparations and ensures the integrity of active ingredients during processing and storage.

[0018] (3) Low-temperature nitrogen protection grinding is used to avoid the loss of heat-sensitive and oxygen-sensitive components during processing. Gradient homogeneous mixing technology takes into account the uniform dispersion of glassy microparticles, phospholipid complexes and crystalline powders. Optional secondary encapsulation of liposomes further improves transmembrane absorption efficiency.

[0019] The technical solution of the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. Attached Figure Description

[0020] Figure 1This is a process flow diagram of the anti-aging ergothioneine-nicotinamide compound preparation, its preparation method, and its application, according to the present invention. Detailed Implementation

[0021] To better understand the above technical solutions, a detailed description of the solutions will be provided below in conjunction with the accompanying drawings and specific embodiments. Obviously, the described embodiments are merely some, not all, of the embodiments of the present invention. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention.

[0022] The terminology used in the embodiments of this invention is for the purpose of describing particular embodiments only and is not intended to limit the invention. The singular forms “a,” “the,” and “the” as used in the embodiments of this invention and the appended claims are also intended to include the plural forms, and “multiple” generally includes at least two unless the context clearly indicates otherwise.

[0023] It should also be noted that the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that an article or device that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such an article or device. Without further limitation, an element defined by the phrase "comprising one..." does not exclude the presence of other identical elements in the article or device that includes said element.

[0024] Example 1 The composition of this embodiment comprises, based on 100 parts by weight of the total weight of PQQ, ergothioneine, and nicotinamide: PQQ 33 parts by weight, ergothioneine 31 parts by weight, nicotinamide 36 parts by weight 9 parts by weight of betaine 15 parts by weight of trehalose 25 parts by weight of quercetin-phospholipid complex, which is pre-combined from quercetin and phospholipids in a mass ratio of 1:2. 12 parts by weight of α-lipoic acid 20 parts by weight of N-acetylcysteine.

[0025] like Figure 1 As shown, the production method is as follows: Step a: PQQ, nicotinamide and betaine are placed in a liquid nitrogen-cooled grinder and ground and mixed under nitrogen protection at a temperature of -60℃ and a purity of 99.9% or higher to obtain premix A; Step b: Ergothioneine and trehalose are dissolved in deionized water at a mass ratio of 1:3, and spray-dried at an inlet air temperature of 180℃ and an outlet air temperature of 90℃ to produce ergothioneine-trehalose glassy microparticles. Step c: Add premix A, the above-mentioned glassy microparticles, quercetin phospholipid complex, α-lipoic acid and N-acetylcysteine ​​to a high-speed homogenizer, mix at 1500 rpm for 2 minutes, then increase the speed by 1000 rpm each time, mix for 1 minute after each increase, until 6000 rpm is reached and mixed continuously for 4 minutes to obtain the active mixture. Step d: Prepare 100g of face cream, the components of which include: 5.0g of active mixture obtained by premixing according to the above ratio, 5.0g of glycerin, 3.0g of butylene glycol, 4.0g of squalane, 3.0g of caprylic / capric triglyceride, 1.5g of hydrogenated lecithin, 1.0g of cetearyl alcohol, 0.2g of carbomer, 0.2g of arginine, 0.5g of 1,2-hexanediol, and the balance of deionized water.

[0026] Deionized water, glycerin, butylene glycol, and carbomer were added to an aqueous phase pot and heated to 80-85°C with stirring until homogeneous, thus obtaining the aqueous phase. Squalane, caprylic / capric triglycerides, cetearyl alcohol, and hydrogenated lecithin were added to an oil phase pot and heated to 80-85°C with stirring until homogeneous, thus obtaining the oil phase. The oil phase was then slowly added to the aqueous phase, and homogenized and emulsified at 3000-4000 rpm for 3-5 minutes to obtain a homogeneous emulsion. After cooling to below 45°C, the active mixture, arginine, and 1,2-hexanediol were added and stirred until homogeneous. Finally, the mixture was cooled to room temperature, defoamed, and packaged to obtain the anti-aging face cream.

[0027] Example 2 The composition of this embodiment comprises, based on 100 parts by weight of the total weight of PQQ, ergothioneine, and nicotinamide: PQQ 34 parts by weight, ergothioneine 34 parts by weight, nicotinamide 32 parts by weight 3 parts by weight of betaine Trehalose 5 parts by weight 10 parts by weight of quercetin-phospholipid complex, which is pre-combined from quercetin and phospholipids in a 1:1 mass ratio. 5 parts by weight of α-lipoic acid 10 parts by weight of N-acetylcysteine.

[0028] The preparation method is the same as in Example 1.

[0029] Example 3 The composition of this embodiment comprises, based on 100 parts by weight of the total weight of PQQ, ergothioneine, and nicotinamide: PQQ 30 parts by weight, ergothioneine 32 parts by weight, nicotinamide 38 parts by weight 15 parts by weight of betaine Trehalose 25 parts by weight 40 parts by weight of quercetin-phospholipid complex, which is pre-combined from quercetin and phospholipids in a mass ratio of 1:3. 20 parts by weight of α-lipoic acid 30 parts by weight of N-acetylcysteine.

[0030] The preparation method is the same as in Example 1.

[0031] Example 4 Based on the formulation of Example 1, 20 parts by weight of urolithin A and 5 parts by weight of spermidine were added. During preparation, urolithin A and spermidine were added in step (c). Premix A, ergothioneine-trehalose glassy microparticles, quercetin phospholipid complex, α-lipoic acid and N-acetylcysteine, as well as urolithin A and spermidine were added to a high-speed homogenizer. The rest of the preparation method was the same as in Example 1.

[0032] A face cream containing the aforementioned anti-aging ergothioneine nicotinamide compound is provided.

[0033] Comparative Example 1 The difference from Example 1 is that the composition does not contain betaine and trehalose, and ergothione is added directly in step c as a raw material powder without being treated in step b.

[0034] Comparative Example 2 The difference from Example 1 is that the composition does not contain quercetin phospholipid complex, but is replaced with an equal mass of uncomplexed quercetin raw material.

[0035] Comparative Example 3 The difference from Example 1 is that the composition does not contain α-lipoic acid and N-acetylcysteine.

[0036] Comparative Example 4 The formulation is exactly the same as that in Example 1, but the manufacturing method adopts conventional process: all components are mixed in a V-type mixer for 30 minutes in an air environment at room temperature and pressure.

[0037] Experimental Example 1 Ergothioneine stability test: The compositions obtained in Example 1, Comparative Example 1, and Comparative Example 4 were placed in a constant temperature and humidity chamber at 40°C, 75% relative humidity, and 4500 Lx light intensity for 30 days. The ergothioneine content in each sample was determined by high performance liquid chromatography (HPLC) on day 0 and day 30, and the retention rate was calculated. Each sample was measured in triplicate, and the average value was taken.

[0038] Table 1 Results of ergothioneine stability test

[0039] The ergothioneine retention rate in Example 1 was as high as 96.5%, indicating that the active ingredient in the composition was effectively protected. In Comparative Example 1, due to the lack of betaine and trehalose, the dual protection of "hydrogen bonds + glassy state" could not be formed, and ergothioneine underwent significant degradation under high temperature, high humidity, and light conditions, with the retention rate decreasing to 78.2%. Comparative Example 4 used a conventional mixing process and operated at room temperature in an air environment. The trace amounts of moisture and oxygen remaining in PQQ and nicotinamide initiated partial degradation of ergothioneine during the processing stage, and the degradation was further accelerated during storage, ultimately resulting in a retention rate of only 65.3%. It is evident that the synergistic protection of betaine and trehalose combined with a low-temperature nitrogen grinding process can significantly inhibit the degradation of ergothioneine during processing and storage, ensuring the long-term stability of the composition.

[0040] Experiment Example 2 Cellular antioxidant and mitochondrial function assays: Human skin fibroblasts were harvested and treated with 400 μmol / L hydrogen peroxide for 4 hours to establish an oxidative damage model. The compositions from Examples 1, 2, 3, and Comparative Examples 1 to 3 were dissolved in serum-free culture medium, filtered through a 0.22 μm filter for sterilization, and treated with the same concentration of active ingredients for 24 hours. A blank control group and a model group were established. The reactive oxygen species scavenging rate was detected using the DCFH-DA fluorescent probe method, mitochondrial membrane potential was detected using the JC-1 staining method, ATP content was detected using the luciferase method, and NAD+ and NADH content were detected and their ratios calculated using an enzyme cycling method. Each group had 6 replicates.

[0041] Table 2 Results of Cellular Antioxidant and Mitochondrial Function Assays

[0042] Examples 1 to 3 showed significantly better performance than their comparative counterparts in all indicators. Comparative Example 1, lacking the protection of betaine and trehalose, experienced partial degradation of ergothioneine during culture medium preparation, resulting in a lower actual effective concentration. ROS scavenging rate, mitochondrial membrane potential, and ATP content were all lower than in Example 1. Comparative Example 2, using unreconstituted quercetin instead of the quercetin phospholipid complex, struggled to activate the SIRT pathway in skin cells and inhibit CD38 enzyme activity. Its NAD+ / NADH ratio was only 3.1, significantly lower than the 4.9 to 5.1 in the example groups, and ATP content was also significantly reduced, indicating the crucial role of quercetin phospholipid recombinant in enhancing the regulation of mitochondrial energy metabolism in skin cells. Example 3 demonstrated the best performance across all indicators. Liposome encapsulation technology further improved the transmembrane delivery efficiency of the active ingredients, allowing PQQ and the quercetin phospholipid complex to enter skin cells and mitochondria more efficiently to exert their effects.

[0043] Experimental Example 3 Evaluation of the anti-aging efficacy of ex vivo skin and organ models: An ex vivo skin-organ culture model using the Franz diffusion cell was employed. Full-thickness abdominal skin from healthy adults was harvested, subcutaneous fat was removed, and the skin was fixed in the diffusion cell with the epidermis facing air and the dermis facing the receiving medium. The culture was conducted at 37°C in a 5% carbon dioxide environment. Four experimental groups were set up: Group A received the receiving medium with the solution of the composition from Example 1 added to a final concentration of 200 μg / mL based on the total amount of active ingredient; Group B received the receiving medium with the solution of the composition from Comparative Example 1 added to the receiving medium at the same concentration; the topical group received a cream containing 5% of the active mixture from Example 1 applied to the skin epidermis every 12 hours; and the control group received only an equal volume of culture medium. Six skin samples were collected from each group and cultured continuously for 7 days. After culture, skin tissue was harvested, and superoxide dismutase activity and malondialdehyde content were measured. Paraffin sections were stained with Masson's stain to observe collagen fiber density, and immunohistochemistry was used to detect the expression level of scutellarin to evaluate skin barrier integrity.

[0044] Table 3. Evaluation results of anti-aging efficacy of isolated skin organ models

[0045] In group A, SOD activity increased to 35.6, MDA content decreased to 1.95, collagen fiber density increased to 41.3%, and the relative expression of scutellarin increased to 2.85, all significantly better than group B and the control group. In group B, lacking the protection of betaine and trehalose, ergothioneine was partially degraded in the culture system, resulting in weakened free radical scavenging ability. The MDA content in group B was 3.18, significantly higher than the 1.95 in group A; simultaneously, the energy metabolism auxiliary effect decreased, and collagen synthesis and scutellarin expression were correspondingly weakened. The topical application group, through direct epidermal absorption, formed a high concentration of active ingredients on the skin, exhibiting the best performance in SOD activity, MDA content, collagen fiber density, and scutellarin expression. The compound formulation exhibits significant advantages in scavenging free radicals, reducing oxidative damage, promoting collagen synthesis, and enhancing barrier protein expression through the synergistic regulation of mitochondria by PQQ, ergothioneine, and nicotinamide, as well as the supplementary synergistic effects of quercetin phospholipid complex, α-lipoic acid, and N-acetylcysteine.

[0046] Therefore, this invention employs the aforementioned anti-aging ergothioneine-nicotinamide compound, its preparation method, and its application. Using PQQ, ergothioneine, and nicotinamide as the core, supplemented by a quercetin-phospholipid complex, it achieves for the first time the synergistic activation of multiple pathways, including mitochondrial regeneration, energy metabolism, free radical targeted scavenging, and mitochondrial quality control. Specifically, PQQ directly promotes mitochondrial biosynthesis, while nicotinamide, as an NAD+ precursor, drives the tricarboxylic acid cycle and oxidative phosphorylation, significantly increasing intracellular ATP levels and providing sufficient energy for skin fibroblasts and various tissue cells, effectively delaying functional aging and combating fatigue. The bioavailability of quercetin is significantly improved after phospholipid complexation, activating the SIRT1 / SIRT3 pathway and complementing PQQ, while simultaneously inhibiting CD38 enzyme activity and reducing NAD+. + The consumption of nicotinamide forms a bidirectional metabolic regulation of "increased synthesis and decreased consumption," further enhancing the improvement effect of mitochondrial energy metabolism.

[0047] Ergothioneine can specifically scavenge strong oxidizing free radicals such as hydroxyl radicals and hypochlorous acid. Combined with alpha-lipoic acid and N-acetylcysteine, it can effectively reduce oxidative stress levels in the skin and body tissues, decrease the production of malondialdehyde (MDA), a lipid peroxidation product, and protect cell membrane integrity. At the skin level, the thorough scavenging of free radicals reduces oxidative damage to collagen and elastin fibers, decreases melanin deposition, and thus significantly improves dull skin and diminishes fine lines around the eyes. Simultaneously, the reduction in oxidative damage helps maintain the normal differentiation and connection of keratinocytes, enhances the skin barrier function, reduces moisture loss, and keeps the skin hydrated and elastic.

[0048] A dual protection system of "hydrogen bonds and glassy state" was constructed through hydrogen bonding between betaine and ergothioneine molecules and a glassy embedding matrix formed by trehalose spray drying. Stable ergothioneine can be efficiently taken up by the transport protein OCTN1, accumulates in skin and mitochondrial-rich tissues, and continuously exerts its free radical scavenging effect, ensuring the long-term efficacy of its effects in clearing skin free radicals, delaying aging, and combating fatigue.

[0049] Utilizing low-temperature nitrogen-protected grinding technology, heat-sensitive and oxygen-sensitive components are micronized and blended under oxygen-free conditions ranging from -50°C to -80°C, effectively preventing activity loss. Gradient homogenization mixing technology ensures uniform dispersion of glassy microparticles, phospholipid complexes, and crystalline powders, guaranteeing a consistent proportion of active ingredients in each product. Optional liposome encapsulation further enhances transmembrane absorption efficiency. The compositions prepared using these processes can serve as core ingredients in topical skin formulations, applied directly to the skin surface to exert antioxidant, free radical scavenging, and skin barrier repair effects, improving dullness and fine lines.

[0050] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can still be made to the technical solutions of the present invention, and these modifications or equivalent substitutions cannot cause the modified technical solutions to deviate from the spirit and scope of the technical solutions of the present invention.

Claims

1. An anti-aging ergothioneine-nicotinamide compound preparation, characterized in that, Based on a total weight of pyrroloquinoline quinone, ergothioneine, and nicotinamide of 100 parts by weight, the compound preparation contains: 30-36 parts by weight of pyrroloquinoline quinone; Ergothioneine 28–34 parts by weight; 32-38 parts by weight of nicotinamide; It also contains: 3 to 15 parts by weight of betaine; Trehalose 5-25 parts by weight; 10-40 parts by weight of quercetin phospholipid complex, wherein the quercetin phospholipid complex is pre-combined from quercetin and phospholipids in a mass ratio of 1:1 to 1:3; 5-20 parts by weight of α-lipoic acid; 10-30 parts by weight of N-acetylcysteine; The preparation method of the compound preparation includes the following steps: (a) Pyrroloquinoline quinone, nicotinamide and betaine were ground and mixed under nitrogen protection and at a low temperature of -50℃ to -80℃ to obtain premix A; (b) Ergothioneine and trehalose were dissolved in deionized water at a mass ratio of 1:2 to 1:5 and then spray-dried to produce ergothioneine-trehalose glassy microparticles. (c) The premix A, the ergothioneine-trehalose glassy microparticles, the quercetin phospholipid complex, α-lipoic acid and N-acetylcysteine ​​are subjected to gradient homogenization, starting at a speed of 1000-2000 rpm and gradually increasing to 5000-8000 rpm to obtain an active mixture. (d) The active mixture is mixed with pharmaceutically acceptable excipients to form an anti-aging composition.

2. The anti-aging ergothioneine-nicotinamide compound preparation according to claim 1, characterized in that, Pyrroloquinoline quinone is at least one of pyrroloquinoline quinone free acid or its derivative; ergothione is L-ergothione; α-lipoic acid is R-α-lipoic acid.

3. The anti-aging ergothioneine-nicotinamide compound preparation according to claim 1, characterized in that, The compound preparation also contains one or more of the following: 5-50 parts by weight of urolithin A, 1-10 parts by weight of spermidine, 10-50 parts by weight of coenzyme Q10, and 50-200 parts by weight of hydrolyzed collagen peptides. During preparation, one or more of urolithin A, spermidine, coenzyme, and hydrolyzed collagen peptides are added in step (c). The premix A, the ergothioneine-trehalose glassy microparticles, the quercetin phospholipid complex, α-lipoic acid and N-acetylcysteine, and one or more of urolithin A, spermidine, coenzyme, and hydrolyzed collagen peptides are subjected to gradient homogenization.

4. The anti-aging ergothioneine-nicotinamide compound preparation according to claim 1, characterized in that, Pharmaceutically acceptable excipients include at least one of the following: fillers, binders, disintegrants, lubricants, sweeteners, flavorings, and glidants.

5. The anti-aging ergothioneine-nicotinamide compound preparation according to claim 1, characterized in that, In step (a), the temperature for low-temperature grinding is -60℃ to -70℃, and the nitrogen purity is above 99.9%.

6. The anti-aging ergothioneine-nicotinamide compound preparation according to claim 1, characterized in that, In step (c), the gradient homogenization is performed as follows: mix at 1000-1500 rpm for 1-3 minutes, then increase the speed by 500-1000 rpm each time, mixing for 1-2 minutes after each increase, until reaching 5000-8000 rpm and continue mixing for 3-5 minutes.

7. The anti-aging ergothioneine-nicotinamide compound preparation according to claim 1, characterized in that, Before step (d), the active mixture is treated with liposome encapsulation technology: the active mixture is dissolved in an organic solvent with phospholipids and cholesterol at a mass ratio of (3-6):1, and a lipid film is formed by vacuum evaporation. The lipid suspension is obtained by adding buffer solution for hydration, and then freeze-drying or spray-drying to make solid liposome powder, which is then mixed with excipients to form a solid liposome powder.

8. The application of an anti-aging ergothioneine-nicotinamide compound preparation as described in any one of claims 1-7, characterized in that, Used to prepare topical skin preparations, which are cosmetics with antioxidant and skin barrier repair functions.

Images